Liminatus Pharma, Inc. (LIMNW) — 10-Q Filings
All 10-Q filings from Liminatus Pharma, Inc.. Browse 3 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (3)
-
Liminatus Pharma's Q3 Loss Widens Amid Post-Merger Operational Surge
— Nov 14, 2025 Risk: high
Liminatus Pharma, Inc. (LIMNW) reported a net loss of $1.82 million for the three months ended September 30, 2025, a significant increase from the $601,372 net -
Liminatus Pharma Narrows H1 Loss Post-Merger, Raises Going Concern Doubts
— Oct 6, 2025 Risk: high
Liminatus Pharma, Inc. (LIMNW) reported a net income of $113,287 for the three months ended June 30, 2025, a significant improvement from a net loss of $(961,20 -
Liminatus Pharma Issues 1M Shares to CEO, Warrants in Q1
— Jun 2, 2025 Risk: high
Liminatus Pharma, Inc. (LIMNW) reported no revenue for the quarter ended March 31, 2025, consistent with its pre-revenue stage as a biological products company.
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX